Point of Care Diagnostics Market Report 2026

The point of care diagnostics market size has grown strongly in recent years. It will grow from $51.62 billion in 2025 to $56.33 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing prevalence of chronic and infectious diseases, expansion of decentralized healthcare models, growing use of glucose monitoring systems, rising demand for quick diagnostic results, increasing awareness of preventive healthcare.

The point of care diagnostics market size is expected to see strong growth in the next few years. It will grow to $81.23 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing development of multiplex testing platforms, rising integration of digital connectivity in diagnostics, expansion of home healthcare diagnostics, growing demand for personalized medicine, increasing adoption of ai-enabled diagnostic tools. Major trends in the forecast period include increasing adoption of rapid diagnostic test kits, rising use of home-based testing devices, growing demand for infectious disease poc tests, expansion of otc diagnostic products, enhanced focus on real-time clinical decision making.

The growing prevalence of chronic and infectious diseases is expected to drive the expansion of the point of care diagnostics market going forward. Chronic diseases are conditions that develop gradually and typically persist for three months or longer. Point of care diagnostics plays an important role in the effective management of chronic diseases and is widely adopted due to its convenience and ability to deliver rapid results. For instance, in 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, 42% of adults in the United States were living with two or more chronic conditions. This trend underscores the increasing burden of multiple chronic diseases within the adult population. Therefore, the rising prevalence of chronic diseases is contributing to the growth of the point of care diagnostics market.

Major companies operating in the point of care diagnostics market are focusing on technological innovations, such as rapid PCR systems, to strengthen their competitive position. Rapid PCR systems are polymerase chain reaction tests designed to deliver results in significantly less time than conventional PCR methods. For instance, in January 2023, Cipla, an India-based pharmaceutical company, introduced its point of care testing device known as Cippoint. This device is engineered to provide fast and accurate diagnostic results for a variety of health conditions. The Cippoint platform features a compact and user-friendly design, making it suitable for use across different settings including hospitals and clinics, and it utilizes advanced technology to support efficient and reliable testing by healthcare professionals.

In July 2024, Roche, a Switzerland-based pharmaceutical company, acquired LumiraDx’s point of care technology for an undisclosed amount. Through this acquisition, Roche aims to expand its diagnostic testing capabilities within primary care environments. LumiraDx is a US-based company specializing in innovative point of care diagnostic solutions.

Major companies operating in the point of care diagnostics market are Abbott Laboratories, Siemens Healthineers AG, Beckman Coulter Inc., Becton Dickinson and Company, Instrumentation Laboratory Company, Nova Biomedical Corporation, Qiagen NV, F Hoffmann La Roche Ltd, Biomeriux SA, Quidel Corporation, Orasure Technologies Inc., Johnson and Johnson, Thermo Fisher Scientific Inc., Sysmex Corporation, Sinocare Inc., Arkray Inc., Danaher Corporation, Chembio Diagnostics Inc., EKF Diagnostics Holdings plc, Trinity Biotech plc, Fluxergy Inc., LumiraDx UK Ltd., Meridian Bioscience Inc., Nipro Europe Group Companies, AccuBioTech Co. Ltd., Atlas Genetics Ltd., Biomeme Inc., Cepheid Inc.

North America was the largest region in the point of care diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the point of care diagnostics market report during the forecast period. The regions covered in the point of care diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point of care diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the point of care diagnostics market by increasing costs of imported reagents, biosensors, microfluidic components, and electronic modules used in diagnostic kits and devices. Diagnostic centers and homecare providers in North America and Europe are most affected due to reliance on imported testing components, while Asia-Pacific faces higher manufacturing input costs. These tariffs are raising device prices and influencing supply availability. However, they are also encouraging local production of diagnostic kits, regional sourcing of consumables, and strengthening domestic POC diagnostics manufacturing ecosystems.

The point of care diagnostics market research report is one of a series of new reports that provides point of care diagnostics market statistics, including point of care diagnostics industry global market size, regional shares, competitors with a point of care diagnostics market share, detailed point of care diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point of care diagnostics industry. This point of care diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Point of care diagnostics refers to medical testing that is carried out at or close to the location where patient care is provided. These diagnostic tests deliver rapid and accurate results that support immediate clinical decision making and patient management.

The primary product types within point of care diagnostics include glucose monitoring kits, infectious disease testing kits, pregnancy and fertility testing kits, hematology testing kits, cardiometabolic monitoring kits, urinalysis testing kits, cholesterol test strips, and others. Glucose monitoring kits are medical devices used to measure blood glucose levels in individuals. These products are available as over the counter devices as well as prescription based devices and are used by a range of end users, including professional diagnostic centers, research laboratories, home care settings, and others.

The point of care (POC) diagnostics market consists of sales of blood glucose meters, pregnancy test kits, and cardiac markers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.